Taylor S H
University Department of Cardiovascular Studies, General Infirmary, Leeds, United Kingdom.
Am J Cardiol. 1994 Jan 27;73(3):28A-33A. doi: 10.1016/0002-9149(94)90271-2.
Calcium antagonists are effective antianginal agents in the treatment of patients with stable exercise-induced angina pectoris. A series of randomized, double-blind, placebo-controlled studies with the novel, once-daily calcium antagonist amlodipine have been completed in a large number of patients with stable exercise-induced angina pectoris. Compared with placebo, once-daily amlodipine demonstrated a significant dose-related extension in exercise duration and workload accomplished, and reduction in number of anginal attacks and associated glyceryl trinitrate consumption. The clinical antianginal attributes of amlodipine were accompanied by significant reductions in electrocardiographic evidence of myocardial ischemia. In comparison with other antianginal drugs, once-daily amlodipine at a dosage range of 5-10 mg demonstrated antianginal activity comparable to thrice-daily diltiazem and once-daily nadolol. Amlodipine administered once daily achieves symptomatic and electrocardiographic amelioration of myocardial ischemic episodes induced by exercise in the majority of patients with stable angina pectoris. Amlodipine does not depress left ventricular pumping activity, and its side-effect profile does not differ substantially from that of placebo.
钙拮抗剂是治疗稳定型运动诱发心绞痛患者的有效抗心绞痛药物。一系列针对新型每日一次钙拮抗剂氨氯地平的随机、双盲、安慰剂对照研究已在大量稳定型运动诱发心绞痛患者中完成。与安慰剂相比，每日一次的氨氯地平在运动持续时间和完成的工作量方面显示出与剂量相关的显著延长，同时心绞痛发作次数和相关硝酸甘油消耗量减少。氨氯地平的临床抗心绞痛特性伴随着心肌缺血心电图证据的显著减少。与其他抗心绞痛药物相比，每日一次剂量为5 - 10毫克的氨氯地平显示出与每日三次地尔硫卓和每日一次纳多洛尔相当的抗心绞痛活性。对于大多数稳定型心绞痛患者，每日一次服用氨氯地平可使运动诱发的心肌缺血发作在症状和心电图方面得到改善。氨氯地平不会抑制左心室泵血活动，其副作用与安慰剂相比无显著差异。
